Andrzej Jakubowiak

University of Illinois Chicago — United States

Medicine · Health Sciences

67h-index22.6kcitations478works6.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(370), Protein Degradation and Inhibitors(183), CAR-T cell therapy research(81), Peptidase Inhibition and Analysis(69), Cancer Treatment and Pharmacology(68)

Publications478 total

Comparative Efficacy of Talquetamab vs. Real-World Physician’s Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent
Advances in Therapy·2025Open Access
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials
UNC Libraries·2025Open Access
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
UNC Libraries·2025Open Access
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial
UNC Libraries·2025Open Access
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma (NDMM) – interim results from the randomized Phase III COBRA trial.
Blood·2025Open Access
Phase II trial of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone in multiple myeloma following BCMA CAR T-cell therapy
Blood·2025
B cell kinetics on next generation sequencing after CAR T-cell therapy in multiple myeloma
Blood·2025Open Access
Carfilzomib, Lenalidomide, and Dexamethasone (KRd) after Autologous Stem-Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: Analysis of High-Risk Subset in Phase 3 ATLAS Trial
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: MM-216 Prophylactic Tocilizumab to Mitigate Cytokine Release Syndrome and Outpatient Dosing of Talquetamab in Relapsed/Refractory Multiple Myeloma: Updated Phase 1/2 Monumental-1 Results
Clinical Lymphoma Myeloma & Leukemia·2025
MM-216: Prophylactic Tocilizumab to Mitigate Cytokine Release Syndrome and Outpatient Dosing of Talquetamab in Relapsed/Refractory Multiple Myeloma: Updated Phase 1/2 Monumental-1 Results
Clinical Lymphoma Myeloma & Leukemia·2025
Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma
Leukemia·2025· 3 citedOpen Access
Current and future role of carfilzomib‐based quadruplet combinations as therapy for newly diagnosed multiple myeloma
HemaSphere·2025· 1 citedOpen Access
Author Correction: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes
Nature Genetics·2025Open Access
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma
Journal of Clinical Oncology·2025· 40 citedOpen Access
Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Journal of Clinical Oncology·2025· 6 cited
Carfilzomib, lenalidomide, and dexamethasone (KRd) as maintenance therapy after autologous stem-cell transplantation (ASCT) in patients with newly diagnosed multiple myeloma (NDMM).
Journal of Clinical Oncology·2025· 1 cited
Intrathecal chemotherapy for ciltacabtagene autoleucel–associated movement and neurocognitive toxicity
Blood Advances·2025· 3 citedOpen Access
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial
The Lancet Oncology·2025· 11 citedOpen Access
Brain-to-vein and vein-to-vein times and outcomes in CAR T-cell therapy in myeloma
Blood Cancer Journal·2025· 3 citedOpen Access
Shaping the future of multiple myeloma therapy: innovations in bispecific antibodies and emerging strategies in Poland
Acta Haematologica Polonica·2025Open Access
page 1 of 24Next →

Frequent Co-authors

Sundar Jagannath(17), Sagar Lonial(16), Paul G. Richardson(13), David S. Siegel(12), Kenneth C. Anderson(11), A. Keith Stewart(10), Ravi Vij(10), Saad Z. Usmani(9), Robert Z. Orlowski(9), Nikhil C. Munshi(8), Jesús F. San Miguel(8), María‐Victoria Mateos(8), Meletios Α. Dimopoulos(7), Jonathan L. Kaufman(7), Nizar J. Bahlis(7), Jesús G. Berdeja(6), Deepu Madduri(6), Myo Htut(6), Enrique Zudaire(6), Jordan M. Schecter(6)